Literature DB >> 9285934

Conversion of angiotensin I to angiotensin II by chymase activity in human pulmonary membranes.

B F Lindberg1, E Gyllstedt, K E Andersson.   

Abstract

An aprotinin-insensitive, angiotensin II (Ang II)-forming chymase has recently been identified in human heart tissue. We studied the hydrolysis of Ang I in human lung membranes. The hydrolysis products Ang II, Ang III, Ang-(1-9), Ang-(2-9), Ang-(1-7) and Ang-(8-10) appeared in membrane preparations from four patients. Two metabolic pathways for the formation of Ang II were identified; one depending on ACE activity (1.4 nmol Ang II/min/mg membrane protein) and the other on serine protease activity (2.1 nmol/min/mg). The serine protease activity was inhibitable to only 30 +/- 8% (mean +/- SEM) by aprotinin, suggesting chymase activity to play a role in the Ang I-conversion of human lung.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9285934     DOI: 10.1016/s0196-9781(97)00011-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Dual inhibition of cathepsin G and chymase reduces myocyte death and improves cardiac remodeling after myocardial ischemia reperfusion injury.

Authors:  Bahman Hooshdaran; Mikhail A Kolpakov; Xinji Guo; Sonni A Miller; Tao Wang; Douglas G Tilley; Khadija Rafiq; Abdelkarim Sabri
Journal:  Basic Res Cardiol       Date:  2017-09-14       Impact factor: 17.165

2.  Ethnic Prevalence of Angiotensin-Converting Enzyme Deletion (D) Polymorphism and COVID-19 Risk: Rationale for Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.

Authors:  Rangaprasad Sarangarajan; Robert Winn; Michael A Kiebish; Chas Bountra; Elder Granger; Niven R Narain
Journal:  J Racial Ethn Health Disparities       Date:  2020-09-08

3.  Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury.

Authors:  Yuntao Wu
Journal:  Virol Sin       Date:  2020-02-07       Impact factor: 4.327

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.